DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The "2018 Diabetic Gastroparesis Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.

With an estimated 3-5 million people in the US suffering from gastroparesis, with young population around 34 years being more susceptible, the Diabetic Gastroparesis presents significant market opportunities of around $5 billion to $6 billion.

Metoclopramide is the only FDA approved drug for treatment of the disease and accordingly, several researchers are focusing on developing new treatment options for the disease. Diabetic Gastroparesis is a GI disorder in which the stomach takes longer periods for emptying the contents.

Around 15 companies and universities are focusing on developing treatment options for Diabetic gastroparesis.

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Diabetic gastroparesis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Diabetic gastroparesis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Diabetic gastroparesis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Key Topics Covered:

1 Figures & Tables

2 Diabetic Gastroparesis Pipeline Analysis

2.1 Disease and Pipeline Overview

2.2 Diabetic Gastroparesis Pipeline Snapshot

2.3 Diabetic Gastroparesis Pipeline by Phase

2.4 Diabetic Gastroparesis Pipeline by Company

2.5 Diabetic Gastroparesis Pipeline by Mechanism of Action

3 Diabetic Gastroparesis- Company Wise Pipeline Analysis

Allergan EndoLogic ETX Pharma Evoke Pharma Shire-Movetis Takeda Pharmaceutical Theravance Biopharma

4 Diabetic Gastroparesis R&D Pipeline Snapshots

Drug wise Pipeline Details Therapeutic Candidate Name Originator Co-Developer/ License Partner Orphan Drug Designation Development Phase Mechanism of Action Current Status Ongoing Clinical Trial Details

5 Recent Developments in Diabetic Gastroparesis Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/pzhgs3/2018_diabetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612006413/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Gastrointestinal Drugs ,Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 03:27 PM/DISC: 06/12/2018 03:27 PM

http://www.businesswire.com/news/home/20180612006413/en